Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes the two are older , I was refering to the most recent ones that were filed , sorry for the confusion
Here is what I was making referecing
Application PCT/US2022/016926 events
Priority claimed from US202163152084P
2022-02-18
Application filed by Cotropia Joseph, Gaurav Chandra
2022-08-25
Publication of WO2022178216A2
2022-09-29
Publication of WO2022178216A3
Here is another example of Enzolytics holding the technology and giving rights to the subsidiary companies, Below is the statement from , the link points out what they want out of patents. The bottom three paragraphs are the key. IMO this is what Enzolytics will hold.
The Company's wholly owned subsidiary Biogenysis, Inc. holds the exclusive license to this technology and manages this technology field for the Company.
Enzolytics, Inc.
April 4, 2023·7 min read
Enzolytics, Inc.
In this article:
ENZC
-1.18%
Watchlist
Watchlist
COLLEGE STATION, TX / ACCESSWIRE / April 4, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).
Enzolytics today announced progress on its ongoing program to produce Monoclonal Antibodies to treat animals by filing a comprehensive patent application covering its identification of conserved neutralizable epitopes on the Feline Leukemia (FeLV) virus. Using the Company's Artificial Intelligence technology, more than 26 immutable epitope sites on the FeLV virus have been identified. These sites are claimed in the filed patent application. The patent covers the use of any of its discovered numerous conserved Feline Leukemia epitopes in the production of monoclonal antibodies, the production of vaccines, or use in diagnostic tests for detecting the virus in cats. The Company's wholly owned subsidiary Biogenysis, Inc. holds the exclusive license to this technology and manages this technology field for the Company.
While the Company's focus is on producing monoclonal antibodies for treating numerous human viruses, including COVID-19, HIV, HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA), the Company has also analyzed epitopes of animal viruses, namely the Cat Feline Leukemia Virus (FeLV), Horse Equine Infectious Anemia Virus, Chicken Anemia Virus, Koala Retrovirus (KoRV), Elephant Endotheliotropic Herpes Virus (EEHV), Avian Flu Swine Flu, This analysis has revealed the conserved immutable sites on these viruses against which monoclonal antibody production is planned. The findings will ultimately be claimed in U.S. and foreign patent applications.
Targeting the conserved sites discovered by Enzolytics allows the production of a therapeutic that will not be rendered ineffective due to mutation (variants) of the virus. Even a "variant form of the virus" will contain the immutable targeted sites. Targeting immutable sites avoids the ineffectiveness that is experienced when a therapeutics or vaccine targets a site that has mutated.
Currently, there is no cure for Cat Feline Leukemia (FeLV) virus. The cost of treatment of the virus is significant. There are more than 45 million cats in the U.S. and over 25% of households in America own one or more cats. FeLV is one of the most common infectious diseases in cats. This virus affects a significant percentage of the cat population in the United States, resulting in millions of cats suffering from it. This same problem exists around the world in the world population of 600 million cats.
Production of monoclonal antibodies targeting this animal virus and bringing this therapy to market will be more direct and the time to treatment of animals will be significantly less than is the case required for monoclonal antibodies developed for the treatment of individuals. The Company has initiated discussions with animal health providers who express an interest in this technology and its end product.
The production of these monoclonal antibodies begins in the Company's lab located at the Texas A&M University Institute for Preclinical Studies [https://tips.tamu.edu/]. The lab uses the Company's proprietary methodology for producing fully species-specific monoclonal antibodies which target conserved, immutable sites on the viruses, thereby avoiding ineffectiveness due to virus mutation.
The methodology implemented by the Company to produce monoclonal antibodies is proprietary and the subject of the Company's pending international patent applications. In the initial process step, Artificial Intelligence (AI - computer analysis) is used to identify conserved, immutable epitopes on the target virus utilizing Enzolytics' proprietary AI platform. In the AI initial analysis process step, the sequences (structure) of virus isolates are analyzed. From that analysis, epitopes (target sites) are identified which are conserved across all isolates curated. The Company production process is then employed to produce monoclonal antibodies targeting these identified conserved sites.
As a part of this process, 3 Dimensional models of these conserved targets are generated, and the targets may be analyzed for linearity, accessibility by antibodies, and neutralizability by antibodies. Then Enzolytics produces multiple broadly neutralizing antibodies targeting these multiple conserved, immutable epitopes on the targeted virus.
Enzolytics' methodology for producing monoclonal antibodies is unique and innovative, unlike those employed by other biotech companies. In the case of a monoclonal antibody to treat an animal virus, the Company's antibodies are produced from animal "immune-B cells", obtained from convalescent animals who have recovered from the target virus. The Company's monoclonal antibodies are then developed directly where the original antibody affinity and specificity are maintained, and the chances of immunogenicity are minimized.
Enzolytics' Focus on Intellectual Property (IP)
"As Enzolytics advances its science and clinical products, the Company continues to build a robust Intellectual Property portfolio", said Gaurav Chandra, MD, the Company COO. "Intellectual property protection is crucial to fostering innovation. Our focus is on gaining competitive advantage through an aggressive patent strategy."
Charles Cotropia, the Company CEO, said, "The patent system is an optimum way for a small biotech company to lay claim, for a 20-year period dating back to an early priority date, to significant intellectual property even before or without bringing the therapeutic to market. The filing of a patent application serves as a constructive reduction to practice of the subject matter described in the application. In this way, we are taking every opportunity to cover the waterfront on all the viruses we are analyzing."
The breadth of patent coverage that is sought and expected is extremely far-reaching based on the discovery of the critical target epitope sites necessary to neutralize these viruses most effectively. The Company has identified conserved epitopes using its AI platform on multiple viruses in addition to HIV and COVID-19, namely HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA). The same has been accomplished in multiple animal viruses. These findings will be the subject of protection through international patents. Patent coverage can be expected covering the discovered conserved epitopes for these human and animal viruses, and additionally on the use of any of the discovered epitopes/antigens in producing therapies, any vaccines or related prophylactic/therapeutic method relating to the identified epitope/antigens and on diagnostics. Our patent portfolio will be extensive."
Enzolytics PCT application fillings I was referencing a few post back are coming up basically on 14-16 months now, so we should be seeing updates on them at anytime. Items are still protected under the filings, so making it to the last step is a great thing. IMO
When making to this stage and filing is what will start moving the deals forward. The animal side was hyped and a very range of treatment was displayed to us and has been very silent lately , watch for this to be the next area invovling deals. Animals trials alot quickier by standars requirements. The Feline leukemia virus treatment was one they were speaking about alot and working with an animal BP. IMO GLTA
https://finance.yahoo.com/news/enzolytics-announces-progress-development-patenting-110000381.html
Remember back when they got opinions back on the application filings that is basically when they would have started filing, if they had the fees ect. to do so.
26) What happens to my application in the national phase?
Once you have entered the national phase, the national or regional patent Offices concerned begin the process of determining whether they will grant you a patent. Any examination which these Offices may undertake should be made easier by the PCT international search report and the written opinion and even more by an international preliminary examination report.
At bottom of 10
Since, in the national phase, each patent Office is responsible for examining your application in accordance with national or regional patent laws, regulations and practices, the time required for the examination and grant of a patent varies across patent Offices.
Nice catch , I was just looking at some filings and ran across that , looking into the patents that they put applications in for I dont see a company but members of the Enzolytics team who are listed as filed by. I provided the links below the click on the PCT # and see what you find. Maybe I missed it . With how Enzolytics has it listed on their website they application filings are for the methodology of the tech. GLTA
https://enzolytics.com/enzolytics-inc-intellectual-property/
https://www.biospace.com/article/releases/enzolytics-inc-announces-u-s-distribution-of-ipf-immune-tm-and-progress-in-each-of-its-therapeutic-platforms/
I believe you are looking for this .
https://www.wipo.int/pct/en/faqs/faqs.html
Here is a Pr from 2022 describing all the Patents they have applications currently filed for. I can not find the list with who actually filed. The write up only mentions the company Enzolytics not the sub companies. Leading one to believe it was under Enzolytics which if true they would have the licensing rights. They may not hold the asset as a dosage or pill form as we are looking at ex ITV1, but hold the protocol and procedures of how it is created, a recipe you could call it. GLTA
https://patentgc.com/patent-application-process/#:~:text=1%20A%20PCT%20application%20is%20filed%20with%20a,the%20patentability%20of%20the%20PCT%20application%E2%80%99s%20subject%20matter.
Just DD GLTA
https://www.marketscreener.com/quote/stock/ENZOLYTICS-INC-120792338/news/Enzolytics-Highlights-Its-Comprehensive-PCT-Patent-Applications-Covering-Discovered-Conserved-Targ-39862907/#:~:text=In%20submissions%20under%20the%20Patent%20Cooperation%20Treaty%20%28PCT%29%2C,diagnostic%20tests%20for%20detecting%20the%20viruses%20in%20patients.
How is your project coming along
Sorry I must have missed it , but they haven't started the trial yet. If so can you please show the PR stating they have started. I agree it would be nice to hear something positive in the trial but that is months off. GLTA
MP just asking because I honesty don't know , what you are describing would that be insider trading? Not that rules are to be broken and goverment offical have done it for years.
This all could be a PIPE dream and nothing goes thru and by then we have the Africa news and we move up. Again why hasn't one of the partners stepped up that should be the 450m question? IMO Held this long whats a few more months, hahhaa
Wouldn't SAGA have to hold the money in sometype of escrow to have the value of the company be 450m so the shares they give to ENZC ( shareholders) have the 10 dollar value?
I understand what your saying , I guess we could say that about our management team too. IMO
I guess what I find a little weird is Samsung, Twist , Intel or any of the other big boys ENZC have mentioned working with after seeing the deal SAGA is trying to do. Not a single one of our partners said hey we will buy the two companies from you and set you up as a NASDAQ spinoff company under our ownership and will leave your management team in tact that we know of. Any of them have the money and means to do so. IMO
I would think with the details they offered us 450m, making whole provisions ect they would have changed it to a bidding agreement instead of a non bidding agreement as far as we know it. IMO GLTA
Interesting read from a few months back. Can't find whether this has been resolved yet. The MSN link sounds very similiar to Enzolytics deal structure deal that didn't work out for AEC. Third link is alittle about the deal and company . Just doing a little DD on who ENZC is trying to work with.
https://www.spacinsider.com/news/deal-announcements-amendments/sagaliam-terminates-arabian-entertainment-deal
https://www.msn.com/en-us/money/companies/spac-sagaliam-extends-closing-deadline-for-arabian-entertainment-deal/ar-AA15IJnk
https://finance.yahoo.com/news/arabian-entertainment-company-ltd-leading-220000359.html
I am saying if you roll into a Roth you have to hold 5 years, before with drawing .
Yes you can roll in a IRA also a Roth at that time you claim taxes the year you do it , and then have a 5 year wait on each deposit rollover. Easier to do it once and done . Some point you pay taxes . How much is depending on the decision you make before investing.
ex 10m in investment gains , at age 70 you have to start withdraw at a ratio of 10% of the account balance . Taxes add up quickly.
So with your holdings you will be approaching them million dollar withdraws and the taxes that come with it. GLTA
You are going to have to draw out starting at 70 years old no matter what and what you say you have made you better start soon so you dont have that big tax bill. No matter how you slice it you will pay taxes on it at a much higher tax rate. Simple math put the same amount in seperate accounts and get the same returns on your investment which would you rather have when it is time to start withdrawing your investment after 59.5 years old, oh the one that doesn't get taxed. You do know you can trade inside a Roth
Oh and you have that tax on that defered amount too.
So let me understand your worried about saving taxes on 6.5k the allowable amount to a Roth that is really smart.
It is nice to know when you have millions you can pull it out at anytime after 59.5 years old and have no taxes I have 2.5 years to go but what a feeling. That is what I say is smart on paying taxes on a 7k deposit up front. Again simple math
This was a lesson for you, instead of knocking people on how they invest. Acting like you are smarter than them ( us ) about investing. I am not saying I am the smartest , just pointing out the flaws in your comment that is how smart investers do it
Good night to you .
If you withdraw a million dollars from an IRA account, you will be taxed based on the type of IRA account you have. If it is a traditional IRA account, you will be taxed at the highest income bracket mandated by the federal government which is 37% for the 2020 tax year1. If it is a Roth IRA account, only contributions to a Roth, not earnings,
I hope that helps. Let me know if you have any other questions.
https://www.forbes.com/advisor/income-tax-calculator/new-york/?deductions=0&filing=single&income=1000000&ira=0&k401=0
https://pocketsense.com/taxes-1-million-dollars-8063543.html
If you are invested that heavy then you will be at a higher tax bracket when withdrawing. I would rather pay a lower tax rate up front and have massive gains with no tax. Think about it, if you are as good as you think . I am retired and have been since I was 49. So please spare me your advice
With all the millions you say you have made in RGBP and here and others then your withdraw rate will be at the top of the tax rate and taxes are due. So what is the tax rate on a million? I know I won't be paying it on what I have made in my Roth and only paid taxes on 7k each years of contributions into it . GLTA
401 and IRA you pay tax on when you cash out. Roth you don't
https://www.investopedia.com/articles/personal-finance/061915/how-your-401k-taxed-when-you-retire.asp
https://www.finra.org/investors/learn-to-invest/types-investments/retirement/managing-retirement-income/taxation-retirement-income
Taxes on IRAs and 401(k)s
Once you start taking out income from a traditional IRA, you owe tax on the earnings portion of those withdrawals at your regular income tax rate. If you deducted any portion of your contributions, you'll owe tax at the same rate on the full amount of each withdrawal. You can find instructions for calculating what you owe in IRS Publication 590, Individual Retirement Arrangements.
Agreed , the other thing as other stated is Saga coming up with the cash before the extentions run out. They are running out of time to start the trials so they get results before that time is up. As you stated missed deadlines all the time , this trial was to start in June as firsted stated then delays. We will all just sit and wait. GLTA
Just thinking about what they PR over a year ago. Think about this 30k@ $10,000 a person that alone would give them 300m. Why would they sell everything for 450m. 10k a dosage is still a savings compared to any treatment out there currently. They have not said what they predicted their cost was going to be that I recall so I just used 10k as an example since the cheapest is approx 27k a year and high end 48k per year. Just thinking GLTA +
ACCESSWIRE
March 14, 2022·5 min read
In this article:
COLLEGE STATION, TX / ACCESSWIRE / March 14, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) Enzolytics' ("ENZC") wholly-owned subsidiary Virogentics, Inc. (the "Subsidiary") today announced its progress toward the production and use of its ITV-1, anti-HIV immunotherapy treatment in the Central and Eastern regions of Africa for patients with HIV/AIDS.
The steps necessary for the production and delivery of the Company's anti-HIV therapy in these regions are in progress. Toxicology, pharmacodynamic and pharmacokinetic studies (toxicology studies) of the immunotherapy are planned, a prerequisite to use of the immunotherapy in certain African countries where the therapies will be used. These toxicology studies will also be used in the Company's progress toward clinical trials necessary for EMA approval. The ITV-1 therapeutic has succeeded in clinical trials earlier and the Company is planning additional trials leading to EMA approval. As that approval is underway, the ITV-1 therapeutic will be provided to the Central and Eastern regions of Africa once toxicology studies are completed.
The Company, led by its CSO Harry Zhabilov and advisor Professor Dr. Luchezar Ivanov, is guiding the production in Eastern Europe using the Company's patented proprietary technology and production process. The Company has commitments for the production of an initial quantity for use in two African hospitals. A follow-on production will be provided to treat a larger group of HIV/AIDS patients followed by a much larger commitment, potentially to treat 30,000 patients in the world total 30m.
Also this is a read worth rereading and look at the numbers they used . This too is from over a year ago. This also is why some feel that they gave the shareholders news that seemed to give the impression this was happening alot sooner than it actually happened and has taking over a year and still actually hasn't happened. No motive here just stating some facts Enzolytics stated to us. GLTA
https://finance.yahoo.com/news/correction-enzolytics-inc-reports-progress-190000692.html
Have a great day and good luck on your project.
MP can we have a great Friday without all the drama of the movement or nonmovement of SP. It is what it is and we all know the pattern thanks to you, either buy more at the cheap price or not and wait for the dividend. Nothing else really matters becauce we are not able to change it.
Enjoy the day , GLTA
No replies on what I have sent, I would say they are under a NDA , or gag order from disclosing anything.
I just asked simple questions like is Enzolytics there
Is a trail being prep to start soon dealing with HIV
Nothing , I really didnt expect much so it wasn't discouraging.
It has to start first then we can look forward to the rest of the story 4 months later or actually 17 weeks. GLTA
I thought the same thing ,
Found alittle information from an old post both companies founded Dec 2020. Also the licence was to the two compaines example below neither company has patents but not saying they haven't filed that i can find
WebJun 13, 2023 · 0 Patents (Medical) associated with Biogenysis, Inc. Login to view more data. 1. News (Medical) associated with Biogenysis, Inc. 27 Apr 2023
I found a patent license agreement between Virogentics, Inc., a wholly-owned subsidiary of Enzolytics, Inc., and the Zhabilov Trust for licensing the U.S. Patent No. 7,479538, entitled Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical1.
https://finance.yahoo.com/news/enzolytics-announces-international-patent-office-103000840.html
https://microcapdaily.com/enzolytics-inc-enzc-publish-white-paper-on-ai-artificial-intelligence-targeting-monoclonal-antibodies/
Enzolytics’ Focus on Intellectual Property (IP)
“As Enzolytics advances its science and clinical products, the Company continues to build a robust Intellectual Property portfolio”, said Gaurav Chandra, MD, the Company COO. “Intellectual property protection is crucial to fostering innovation. Our focus is on gaining competitive advantage through an aggressive patent strategy.”
The Company has proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases which are currently being employed to produce monoclonal antibody therapeutics for treating the CoronaVirus (SARS-CoV-2), HIV-1 and the Feline Leukemia virus. The Company has also identified conserved epitopes on and has plans to produce mAbs targeting many other viruses, including HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA). The Company has also analyzed epitopes of animal viruses and plans to produce mAbs for treating these animal viruses.
Enzolytics has pending international patent applications covering the use of any of its discovered numerous conserved Coronavirus epitopes or conserved HIV epitopes in the production of monoclonal antibodies, the production of vaccines or use in diagnostic tests for detecting the viruses in patients1. Enzolytics is also the owner of the following issued U.S. Patents covering its technology relating to a peptide that has been demonstrated in clinical trials to provide anti-HIV-1 retroviral benefit in vivo2.
https://www.biospace.com/article/releases/enzolytics-inc-files-provisional-patent-for-treatment-of-multiple-sclerosis/
https://www.accesswire.com/633958/Enzolytics-Announces-the-Discovery-and-Patenting-of-8-Newly-Identified-Conserved-Target-Sites-on-the-HIV-1-Virus
https://enzolytics.com/enzolytics-inc-intellectual-property/
Enzolytics, Inc. has a pending patent covering the proprietary methodology for producing fully human neutralizing monoclonal antibodies against infectious diseases, including Rabies, influenza A, influenza B, Tetanus, Diphtheria, HIV-2, Anthrax, Smallpox, H1N1 influenza, Herpes Zoster, Varicella Zoster and Ebola1
Credit goes to
falon
Re: airmikeyy post# 70125
Saturday, January 30, 2021 7:12:29 PM
Post#
70174
of 181830
Two Patent License Agreements
On November 30, 2020, Biogenysis, Inc., a wholly-owned subsidiary of Enzolytics, Inc., entered into a Patent License Agreement with Bioclonetics in order to license the U.S. Provisional Patent Application No. 63/078,482, filed September 15, 2020, entitled NOVEL HIV-BINDING PEPTIDES for treating, preventing and reducing the risks of HIV, including all patents issuing therefrom and any foreign counterparts thereof.
Also on November 30, 2020, Virogentics, Inc., a wholly-owned subsidiary of Enzolytics, Inc.,entered into a Patent License Agreement with the Zhabilov Trust in order to license the U.S. Patent No. 7,479538, entitled Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical composition the same for detecting preventing and treating HIV; U.S. Patent No. 8,066982, Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical composition compressing the same for detecting preventing and treating HIV, including all patents issuing therefrom and any foreign counterparts thereof.
https://backend.otcmarkets.com/otcapi/company/financial-report/265788/content
Patent US-7479538
Enzolytics has a License Agreement for US Patent 7479538. The claim is Irreversibly-inactivated Pepsinogen Fragments for Modulating Immune Function.
https://enzolytics.com/patent
DYNO
You also have as 29 said 401's which in most cases have higher deposit allowed you have to look into what is allowed, state employees have an optional 457 plans that allow deposit limits of 20k per year. Thoses also save on taxes upfront , you pay taxes as it is drawn out in retirement adding to your income tax at that point.
https://www.kiplinger.com/retirement/retirement-plans/603952/457-contribution-limits-for-2022
https://www.forbes.com/advisor/retirement/401k-contribution-limits/
Again look into all your options and what meets your needs long term and tax liabilities . Good luck.
IMO I think it will come down to the licence rights , the Trust controls which has given exclusive rights to Enzolytics. Was this given away in the proposed deal or not? We don't know until they release the details of the deal. Patents that Enzolytics have told us they filed over the past year or two as far as we know where filed under their name not the two subsidiaries ( have not been able to track that down actually who's name the patents were filed under ) but I don't think the two sub companies were created yet. Keep in mind that CC said he was building a portfolio for licencing. I think a big tell is what is happening with CC his brother and Gaurav shares , their is alot between the 3 of them I can't believe they are not getting anything for all of them, if we see some filings that would be a good thing to look at if they are converting or are they still there. IMO
https://www.civilianintelligencenetwork.ca/2021/10/30/covid-cure-found-monoclonal-antibody-clone-3-intel-corporation-is-your-new-master/#:~:text=%28Now%20Enzolytics%20Inc.%29%20holds%20the%20patent%20to%20GP41,the%20cure%20for%20HIV%2C%20SARS-CoV-2%20and%20several%20Cancer.
https://uspto.report/patent/grant/8,066,982
https://pubchem.ncbi.nlm.nih.gov/patent/US-7479538-B2
Dyno
If you are young and have time to save look into Roth IRAs
The amount of deposit to a Roth or IRA have a cap, here is a reference . Always verify what is being said . Good luck in your investment
https://www.aarp.org/retirement/planning-for-retirement/info-2023/ira-contribution-limits-2023.html?cmp=KNC-DSO-COR-Core-Retirement-NonBrand-Phrase-44603-Bing-RETIREMENT-Contribution-Phrase-NonBrand&gclid=627e535141d516a4fa2d37e1d9d360c3&gclsrc=3p.ds&msclkid=627e535141d516a4fa2d37e1d9d360c3&utm_source=bing&utm_medium=cpc&utm_campaign=Core-Retirement-NonBrand-Phrase&utm_term=maximum%20contribution%20to%20ira&utm_content=Contribution
It is a sit and wait game again. No definite details so we all will be guessing until they are released in a finished signed deal.
It has been fun but I think I will check in once and awhile to see if anything is new. I am holding my shares atleast thru this transaction occurs. No need to read speculation day in day out , nothing we can do that will change the outcome.
Three choice as stated many times Buy Hold Sell. See you when the deal is done and maybe the club will have staff and new members to welcome.
MP take a long break and decompress you did what you could but the game has changed so just go with it. YOU or anyone else isn't going to change it and I mean that in a good way not a jab at anyone. We are still missing to much of the puzzle to say one way or another what we will actually recieve. GLTA
I would think a new board could be made now , SAGA is the company and is active now no board is here in IHUB . The two companies will fall under SAGA as far as being on a trading board. The same topics could be discussed on a new board since it involves SAGA ? IMO
So how do we start a new board with the new name ? GLTA
The next big question is are we now going to be in this .047x - .05xx range for the next 6 to 8 months? GLTA
A few questions
We know that they have shared something with Samsung , Abveris for sure they have stated that , speculation about Gilead and Regeneron why isn't one of theses companies buying Enzolytics two subsidiaries for more than 450m? They would have everything related to cures ect for a rock bottom price?
Just a thought years of research ect.. multiple studies saying the science works yet they still are going thru new trials and without starting never the less no completed results in hand they are selling off everything. Is it because the past is actually to hard to cleanup, so this is the best option?
Again why isn't any of the companies we have heard about or theorized ties to Enzolytics not stepping up to own the future?
I am holding to see what happens so not bashing just trying to ask why a company that promoted so much and selfed valued in the billions per year settles for less than 1/2 billion for everything. GLTA
Why bother at this point
Enzolytics, Inc. v. Kona Concepts, Inc.
Court Docket Sheet
District of Delaware
1:2021-cv-01600 (ded)
68) 07/11/2023OBJECTIONS by Kona Concepts, Inc. to [64] REPORT AND RECOMMENDATIONS re [44] MOTION to Dismiss Counterclaim filed by Enzolytics, Inc. Please note that when filing Objections pursuant to Federal Rule of Civil Procedure 72(b)(2), briefing consists solely of the Objections (no longer than.
If true yes they would, but as stated by them this is an Example so until they actually post what the deal is people that believed in ENZC now are a little leery due to what has been said in the past and what has actually happened. GLTA
Jim you have any thoughts on all this, this now puts you and others outside their time frame? GLTA